Vor Biopharma's (VOR) Buy Rating Reaffirmed at HC Wainwright

Key Points

• Vor Biopharma has received a "buy" rating from HC Wainwright, with a price target of $3.00, indicating a potential upside of 48.51% from its previous close.
• Recently, other analysts have downgraded Vor Biopharma from "strong-buy" to "hold," but the overall consensus rating remains a "Moderate Buy" with a target price of $5.63.
• Institutional investors own 97.29% of Vor Biopharma's stock, with significant recent purchases from firms like Goldman Sachs Group Inc. and Money Concepts Capital Corp.

Vor Biopharma (NYSE:VOR - Get Free Report)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $3.00 price target on the stock. HC Wainwright's price target suggests a potential upside of 40.19% from the company's current price. HC Wainwright also issued estimates for Vor Biopharma's FY2028 earnings at $0.03 EPS and FY2029 earnings at $0.21 EPS.

Several other equities analysts have also recently issued reports on VOR. JMP Securities reiterated a "market perform" rating and issued a $6.00 price target on shares of Vor Biopharma in a report on Friday, May 9th. Citizens Jmp lowered Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 9th. Jones Trading lowered Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Wedbush reaffirmed an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Finally, Baird R W lowered Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $6.07.

Vor Biopharma Price Performance

Shares of VOR stock traded up $0.16 during trading hours on Thursday, hitting $2.14. 3,673,478 shares of the company's stock were exchanged, compared to its average volume of 8,037,786. The stock's 50-day moving average is $1.59 and its 200-day moving average is $1.04. The stock has a market cap of $271.10 million, a price-to-earnings ratio of -1.30 and a beta of 2.06. Vor Biopharma has a 52 week low of $0.13 and a 52 week high of $3.29.

Institutional Trading of Vor Biopharma

Institutional investors and hedge funds have recently modified their holdings of the stock. RA Capital Management L.P. grew its holdings in Vor Biopharma by 74.3% during the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock valued at $44,007,000 after purchasing an additional 16,897,159 shares during the period. Lynx1 Capital Management LP bought a new position in shares of Vor Biopharma in the fourth quarter worth $707,000. Jane Street Group LLC bought a new stake in Vor Biopharma during the first quarter valued at $140,000. OMERS ADMINISTRATION Corp purchased a new position in Vor Biopharma during the first quarter worth about $100,000. Finally, Trustees of Columbia University in the City of New York purchased a new position in Vor Biopharma during the fourth quarter worth about $102,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.